FDA approves pembrolizumab plus chemoradiotherapy to treat FIGO 2014 stage III-IVA cervical cancer Jan. 16, 2024 The Food and Drug Administration has approved pembrolizumab, an anti-programmed death receptor-1 therapy, plus chemoradiotherapy, to treat individuals with International Federation of Gynecology and Obstetrics 2014 stage III-IVA cervical cancer. Pharmacy Times
Connecting with Dean Hyochol Brian Ahn Jan. 16, 2024 New Nursing dean says technology, including AI, will enhance research and education to reach even more of those in need of care. Read more Image
Health Sciences Impact Annual Report shares our best work Jan. 16, 2024 Before we get too far into 2024, I’d like to share with you one of our final projects of 2023, the inaugural Health Sciences Impact Annual Report. Read more
Stephenson named one of top 50 women leaders in medicine Jan. 16, 2024 Stephenson named one of top 50 women leaders in medicine Read more Image
Arizona Center for Rural Health January newsletter Jan. 16, 2024 Arizona Center for Rural Health Read more
Zuckerman College of Public Health January 2024 newsletter Jan. 12, 2024 Mel and Enid Zuckerman College of Public Health Read more
Innovative breakthrough: Genetically engineered stem cells to evade immune rejection Jan. 12, 2024 New research led by Deepta Bhattacharya, PhD, professor at the College of Medicine – Tucson, could open new opportunities for stem cell therapies. Bhattacharya's team genetically modified pluripotent stem cells to avoid immune rejection. BNN
Researchers genetically modify stem cells to evade immunological rejection Jan. 11, 2024 University of Arizona Health Sciences researchers say the genetically engineered stem cells also could pave the way for new regenerative medicine treatments for diseases such as Type 1 diabetes. Read more Image
